 |
|
Gastroesophageal Reflux DiseaseCurrent Strategies for Patient Management
Donald O. Castell, MD;
Brian T. Johnston, MD
Arch Fam Med. 1996;5(4):221-227.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Castell DO. Gastroesophageal reflux disease: the great mimic. Gastrointest Dis Today. 1994;3:1-7.
2. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc. 1994;69:867-876.
PUBMED
3. Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med. 1991;90:576-583.
PUBMED
4. Wiener GJ, Koufman JA, Wu WC, Cooper JB, Richter JE, Castell DO. Chronic hoarseness secondary to gastroesophageal reflux disease: documentation with 24-hour ambulatory pH monitoring. Am J Gastroenterol. 1989;84:1503-1508.
PUBMED
5. Sontag SJ, O'Connell S, Khandelwal S, et sl. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology. 1990;99:613-620.
PUBMED
6. Garnett WR. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease. Am J Hosp Pharm. 1993;50:S11-S18.
ABSTRACT
7. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51:59-67.
PUBMED
8. Goldberg HI, Dodds WJ, Gee S, Montgomery C, Zboralske F. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology. 1969;56:223-230.
PUBMED
9. Zaninotto G, DiMario F, Costantini M, et al. Oesophagitis and pH of refluxate: an experimental and clinical study. Br J Surg. 1992;79:161-164.
PUBMED
10. Smith JL, Operkun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989;96:683-689.
PUBMED
11. Hogan WJ. Gastroesophageal reflux disease: an update on management. J Clin Gastroenterol. 1990;12:S21-S28.
PUBMED
12. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol. 1995;268(pt 1):G128-G133.
PUBMED
13. Mittal RK. Current concepts of the anti-reflux barrier. Gastroenterol Clin North Am. 1990;19:501-516.
PUBMED
14. Lin S, Ke M, Xu J, Kahrilas PJ. Impaired esophageal emptying in reflux disease. Am J Gastroenterol. 1994;89:1003-1006.
PUBMED
15. Ott DJ. Barium esophagram. In: Castell DO, Wu WC, Ott DJ, eds. Gastro-esophageal Reflux Disease: Pathogenesis, Diagnosis, Therapy. Mount Kisco, NY: Futura; 1985:109-128. 16. Ott DJ, Chen YM, Gelfand DW, Munitz HA, Wu WC. Analysis of a multiphasic radiographic examination for detecting reflux esophagitis. Gastrointest Radiol. 1986;11:1-6.
PUBMED
17. Richter JE, Castell DO. Gastroesophageal reflux: pathogenesis, diagnosis, and therapy. Ann Intern Med. 1982;97:93-103.
FREE FULL TEXT
18. Bernstein LM, Baker LA. A clinical test for esophagitis. Gastroenterology. 1985;34:760-781.
19. Klauser AG, Heinrich C, Schindlbeck NE, Muller-Lissner SA. Is long-term esophageal pH monitoring of clinical value? Am J Gastroenterol. 1989;84:362-366.
PUBMED
20. Richter JE. A critical review of current medical therapy for gastroesophageal reflux disease. J Clin Gastroenterol. 1986;8:72-80.
PUBMED
21. Castell DO. Medical therapy for reflux esophagitis: 1986 and beyond. Ann Intern Med. 1986;104:112-114.
FREE FULL TEXT
22. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol, and antacid foam tablets on gastroesophageal reflux. Dig Dis Sci. 1981;26:673-680.
PUBMED
23. Becker DJ, Sinclair J, Castell DO, Wu WC. A comparison of high and low fat meals on postprandial esophageal acid exposure. Am J Gastroenterol. 1989;84:782-786.
PUBMED
24. Waring JP, Eastwood TF, Austin JM, Sanowski RA. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am J Gastroenterol. 1989;84:1076-1078.
PUBMED
25. Higgs RH, Smyth RD, Castell DO. Gastric alkalinization: effect on lower-esophageal-sphincter pressure and serum gastrin. N Engl J Med. 1974;291:486-490.
PUBMED
26. Castell DO, Dalton CB, Becker D, Sinclair J, Castell JA. Alginic acid decreases postprandial upright gastroesophageal reflux. Dig Dis Sci. 1992;37:589-593.
PUBMED
27. Lieberman DA. Medical therapy for chronic reflux esophagitis: long-term follow-up. Arch Intern Med. 1987;147:1717-1720.
FREE FULL TEXT
28. Behar J, Sheahan DG, Biancani P, Spiro H, Storer EH. Medical and surgical management of reflux esophagitis: a 38-month report of a prospective clinical trial. N Engl J Med. 1975;293:263-268.
ABSTRACT
29. Verlinden M. Review article: a role for gastrointestinal prokinetic agents in the treatment of reflux esophagitis. Aliment Pharmacol Ther. 1989;3:113-131.
PUBMED
30. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther. 1993;7:4-12.
31. Freston JW. Future prospects for proton pump inhibitors. Aliment Pharmacol Ther. 1993;7:68-75.
PUBMED
32. Klinkenberg-Knol EC, Jansen JM, Festen HP, Meuwissen SG, Lamers CB. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet. 1987;1:349-351.
PUBMED
33. Havelund T, Laursen LS, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative trial. BMJ. 1988;296:89-92.
FREE FULL TEXT
34. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicentre study. Scand J Gastroenterol. 1988;23:625-632.
PUBMED
35. Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine for the treatment of patients with reflux oesophagitis not responding to standard doses of H2-receptor antagonists. Aliment Pharmacol Ther. 1990;4:145-155.
PUBMED
36. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive esophagitis. Aliment Pharmacol Ther. 1995;9:25-31.
PUBMED
37. Feldman M, Harford WV, Fisher RS, et al. Treatment of reflux esophagitis resistant to H2receptor antagonists with lansoprazole, a new H+/ K+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol. 1993;88:1212-1217.
PUBMED
38. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121:161-167.
FREE FULL TEXT
39. Corallo J, Vicari F, Forestier S, et al. Lansoprazole in acute treatment of reflux esophagitis. Gastroenterology. 1993;104:58. Abstract.
40. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in the short-term treatment of reflux oesophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol. 1993;28:224-228.
PUBMED
41. Sekiguchi T, Horikoshi T, Nishioka T, et al. Clinical effect of proton pump inhibitors on reflux esophagitis. Nippon Rinsho. 1992;50:131-137.
PUBMED
42. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994;48:1-27.
PUBMED
43. Robinson M, Lanza F, and the Lansoprazole Study Group. Lansoprazole for one year prevents recurrence of erosive reflux esophagitis. Gastroenterology. 1994;106:166. Abstract.
44. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology. 1994;107:1312-1318.
PUBMED
45. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35(suppl_1):42-55.
PUBMED
46. Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG. The effects of Iansoprazole, a new H+, K+-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther. 1992;6:359-372.
PUBMED
47. Dayal Y, Berlin R, Collen M, Bhatnager R. Does prolonged omeprazole (OME) administration affect enterochromaffin-like (ECL) cell populations in hypersecretors? Gastroenterology. 1989;96:113. Abstract.
48. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther. 1993;7:56-60.
PUBMED
49. Brunner G, Creutzfeldt W. Omeprazole in the long-term treatment of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol. 1989:24:101-105.
50. Spechler SJ, and the Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med. 1992;326:786-792.
ABSTRACT
51. Brand DL, Eastwood IR, Martin D, Carter WB, Pope CE II. Esophageal symptoms, manometry, and histology before and after antireflux surgery: a long-term follow-up study. Gastroenterology. 1979;76:1393-1401.
PUBMED
|
